Diabetic Ulcer Treatment Market 2021 Technology Development, Key Manufacturers, Forecast Based on Major Drivers and Trends Up to 2028
The Global Diabetic Ulcer Treatment Market
size is projected to reach USD 13.53 billion by the end of 2027. The increasing
prevalence of diabetes will create several growth opportunities for the
companies operating in the market.
Diabetic ulcers are
the most common symptom for patients with uncontrolled or unattended diabetes.
These are severe conditions and can affect the bottom of your feet as well as
the bones in this area. Almost all people suffering from diabetes are exposed
at the risks of ulcers. The treatment of these ulcers can vary from patient to
patient as well as the severity of the condition. The treatment can also vary
depending on the cause of the ulcer. The severe symptoms associated with foot
ulcers such as swelling, discomfort in walking, and redness and irritation, have
led to a huge emphasis on the early detection and treatment of the disease.
Additionally, mouth ulcers can also cause a lot of discomfort and pain and
ultimately impede speech. The increasing investment in the development of
efficient treatment options will have a direct impact on the growth of the
overall diabetic ulcers treatment market in the coming years.
Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetic-ulcer-treatment-market-102412
List of companies profiled in the
report:
• Coloplast Corp (Denmark)
• Smith & Nephew (UK)
• ConvaTec Group Plc (UK)
• Mölnlycke Health Care AB.(Sweden)
• 3M (U.S.)
• Integra LifeSciences Corporation.
(U.S.)
• Cardinal Health. (U.S.)
• Tissue Regenix (U.K)
• B. Braun Melsungen AG (Germany)
Increasing Number of
Regulatory Approvals Will Provide Impetus to Market Growth
The report encompasses
several factors that have contributed to the growth of the overall market in
recent years. Among all factors, the increasing number of regulatory approvals
by leading organizations such as the Food and Drug Administration (FDA) has
made the highest impact on market growth. In December 2017, SANUWAVE Health,
Inc. announced that it has received approval from the US Food and Drug
Administration for the marketing of its latest product for treatment of ulcers.
The company claims that the ‘Dermaspace System’ is a shock-wave intended device
that can be used to treat diabetic foot ulcers. SANUWAVE’s latest shock-wave
device will not just benefit the company but will have a direct impact on the
growth of the overall market in the coming years. The report highlights a few
of the other products, similar to this, that have also made a considerable
impact on market growth.
Quick Buy This Research
Report: https://www.fortunebusinessinsights.com/checkout-page/102412
Industry Developments:
December 2019: Orpyx Medical Technologies Inc. announced the
launch of a new patient monitoring system. The Orpyx SI (Sensory Insoles) is a
device integrated with remote patient monitoring system, that can be used for
the prevention of diabetic foot ulcer and neuropathy-related ulcers.
About Us:
Fortune
Business Insights™ offers expert corporate analysis and accurate data, helping
organizations of all sizes make timely decisions. We tailor innovative
solutions for our clients, assisting them address challenges distinct to their
businesses. Our goal is to empower our clients with holistic market
intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis
to help companies achieve sustainable growth. Our team of experienced analysts
and consultants use industry-leading research tools and techniques to compile
comprehensive market studies, interspersed with relevant data.
Contact Us:
Fortune
Business Insights Pvt. Ltd.
9th
Floor, Icon Tower, Baner - Mahalunge Road,
Baner,
Pune-411045,
Maharashtra,
India.
Phone:
US
:+1 424 253 0390
UK
: +44 2071 939123
APAC
: +91 744 740 1245
Email:
mailto:sales@fortunebusinessinsights.com
Comments
Post a Comment